In a double blind placebo controlled randomised parallel study the
antihypertensive activity and adverse biochemical effects of three doses of
cyclopenthiazide were evaluated in patients with mild
essential hypertension that had been recently diagnosed or was being treated with a single
drug. After a four week placebo washout period 53 patients with diastolic blood pressures between 90-110 mm Hg were randomly assigned to 50, 125, or 500 micrograms
cyclopenthiazide or matching placebo for an eight week period of treatment. Blood pressure was measured in the patients' homes by the same observer every two weeks. Serum
urea,
electrolytes,
urate, and
creatinine concentrations and 24 hour urinary
sodium excretion were monitored every four weeks and serum
magnesium concentration and plasma
renin activity at the end of the washout and treatment periods. After eight weeks of treatment systolic and diastolic blood pressures were significantly reduced in patients taking 125 and 500 micrograms
cyclopenthiazide when compared with those taking placebo. The decrement in serum
potassium concentration (0.6 mmol/l) and increase in serum
urate concentration 0.06 mmol/l) were greatest with the 500 micrograms dose, the increase in serum
urate concentration alone being significant. No change in serum
magnesium concentration or 24 hour urinary
sodium excretion was noted with any dose of
cyclopenthiazide. Only the 500 micrograms dose of
cyclopenthiazide significantly increased the mean plasma
renin activity (1.8 (95% confidence interval 0.2 to 3.4)-5.4 (3.9 to 6.8) nmol
angiotensin I/l/h); the other doses like the placebo had no effect.
Cyclopenthiazide 125 micrograms, a dose lower than is currently marketed, produced a similar hypotensive response to 500 micrograms of the
drug without upsetting the biochemical profile.